Articles tagged "Immunosuppression"

2017 American Transplant Congress
Emerging Variables Which May Enhance Care of HIV Positive Renal Transplant Recipients.
D. Leonard, M. Prendergast.
Transplantation, Mayo Clinic, Jacksonville, FL
Purpose: Single center experience of kidney and pancreas transplantation in the HIV positive populationMethods: Retrospective data and outcomes analysis of HIV positive kidney and pancreas…
2017 American Transplant Congress
Treatment of Post-Transplant Nephrotic Syndrome with Adrenocorticotropic (ACTH) Gel.
A. Khalil,² A. Karabala,¹ A. Sharfuddin,² M. Grafals.¹
¹Medstar Georgetown Transplant Institute, Washington DC; ²Indiana University Health, Indianapolis
Objectives: Post-kidney transplant proteinuria due to recurrent GN is considered to be a significant risk factor negatively affecting kidney transplant survival. In this case series…
2017 American Transplant Congress
CD4⁺/CD8⁺ T Cell Ratio as a Predictive Marker for Early Graft Failure in Pig to Non-Human Primate Islet Xenotransplantation with Immunosuppression.
S. Choi,^1,3,4 H.-J. Kim,^1,2,3,4 I.-H. Yoon,^1,2 J.-S. Kim,^1,2,6 S.-J. Kang,^1,2,3,4 H.-Y. Nam,^1,2 B.-H. Min,¹ J.-S. Shin,^1,6 J.-M. Kim,^1,6 Y.-H. Kim,^1,5 W.-W. Lee,^1,2,3,4 C.-G. Park.^1,2,3,4,6
¹Xenotransplantation Research Center, Seoul National University College of Medicine, Seoul, Korea; ²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea; ³Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea; ⁴Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea; ⁵Department of Microbiology, Kyungpook National University School of Medicine, Daegu, Korea; ⁶Institute of Endemic Diseases, Seoul National University College of Medicine, Seoul, Korea
Background: Outstanding results from nonhuman primate study put islet xenotransplantation with immunosuppression closer to the clinical application. To establish successful immune suppressive protocols, immune monitoring…
2017 American Transplant Congress
Predictors of Malignancies Across Solid Organ Transplantation.
M. Bhat,¹ K. Mara,² R. Dierkhising,² K. Watt.³
¹Multi Organ Transplant Program, University Health Network, Toronto, ON, Canada; ²Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN; ³Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
Background & Aims:Solid organ transplant recipients are at much higher risk of cancer as compared to the general population. The aim of this study was…
2017 American Transplant Congress
Prevalence of CYP3A Genomic Variances and Impact on Tacrolimus Dosing Requirements in Kidney Transplant Recipients in Eastern North Carolina.
T. Asempa,¹ S. Hudson,² L. Rebellato,² A. Maldonado.¹
¹Vidant Medical Center, Greenville, NC; ²East Carolina University, Greenville, NC
BACKGROUND: African American (AA) patients are substantially more likely to express CYP3A5. Presence of CYP3A5 polymorphisms is an important pharmacotherapeutic consideration due to the extensive…
2017 American Transplant Congress
Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Dosing.
D. Hesselink,¹ L. Andrews,² B. de Winter,² J. Tang,³ N. Shuker,² R. Bouamar,² R. van Schaik,⁴ B. Koch,² T. Van Gelder.¹
¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands; ²Hospital Pharmacy, Erasmus MC, Rotterdam, Netherlands; ³Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China; ⁴Clinical Chemistry, Erasmus MC, Rotterdam, Netherlands
Bodyweight-based dosing of tacrolimus (Tac) is considered standard care, even though the available evidence is thin. An increasing proportion of transplant recipients is overweight, prompting…
2017 American Transplant Congress
Everolimus Reduces Carotid Intima-Media Thickness in Renal Transplant Recipients After One Year: Randomized Controlled Trial.
P. Garcia, H. Takase, H. Nga, M. Contti, J. Hueb, L. Morales-Buenrostro.
Internal Medicine, Botucatu Medical School - Universidade Estadual Paulista, Botucatu, São Paulo, Brazil
Cardiovascular disease remains the commonest cause of death in kidney transplant recipients. Although some studies suggest that Mammalian target of rapamycin (mTOR) inhibitors may reduce…
2017 American Transplant Congress
The Impact of Tacrolimus and MPA Derivative Immunosuppression on Acheived GFR in Recipients without Rejection: A Comparison of GFR of Living Donor Recipient Pairs at Six Months Post-Transplant.
D. Keith.
Medicine, Division of Nephrology, Sacred Heart Hospital, Pensacola, FL
Analysis of the difference in estimated GFR (eGFR) of living donor recipient pairs at six months post-transplant showed that increased use of tacrolimus and MPA…
2017 American Transplant Congress
Disease Progression on Neoadjuvant Chemotherapy Is a Strong Predictor of Recurrence for Pediatric Hepatoblastoma.
M. Kueht,¹ S. Commander,¹ T.-A. Ha,¹ A. Rana,^1,2 Y. Shi,¹ S. Vasudevan,^1,2 J. Goss.^1,2
¹Surgery, Baylor College of Medicine, Houston; ²Surgery, Texas Children's Hospital, Houston
Purpose. In addition to peri-operative chemotherapy, proper triage between orthotopic liver transplantation (OLT) and partial hepatectomy (PH) is critical to limiting disease recurrence in pediatric…
2017 American Transplant Congress
Saftey & Long Term Outcomes of Tocilizumab (Anti-IL6R, TCZ) Therapy in Treatment of Chronic Antibody Mediated Rejection (CABMR) & Transplant Glomerulopathy (TG) in Highly-HLA Sensitized (HS) Patients (PTs).
J. Choi,¹ O. Aubert,² A. Vo,¹ A. Loupy,² M. Haas,³ S. Louie,¹ A. Kang,¹ A. Peng,¹ R. Najjar,¹ E. Huang,¹ M. Toyota,⁵ X. Zhang,⁴ S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Paris Transplant Group, University Paris Descartes, Paris, France; ³Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, CA; ⁴Department of HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ⁵Transplant Immunology Lab, Cedars-Sinai Medical Center, Los Angeles, CA
Introduction: DSAs in HS pts lead to poor allograft survival & return to a dialysis. Treatment options for CABMR and TG are limited. IL-6 appears…